Head-to-Head Comparison of Tapentadol Nasal Spray and Intravenous Tramadol for Managing Postoperative Moderate-to-Severe Pain: An Observational Study

Abstract

Abstract Background: Tapentadol is known for its opioid-sparing effect, reducing adverse effects associated with opioids, particularly gastrointestinal issues. However, limitations in the oral formulation warrant exploration of alternatives like tapentadol nasal spray for enhanced efficacy and patient experience. Aims and Objectives: This investigator-initiated trial aimed to assess the safety of tapentadol nasal spray (45mg/dose, administered four times daily) compared to intravenous tramadol (50mg twice daily) in patients with post-operative moderate to severe pain over a 3-day period. Materials and Methods: A randomized, open-label real-world trial enrolled 600 patients. Pain management efficacy, sleep scores, and patient comfort and convenience were evaluated. Results: Tapentadol nasal spray demonstrated superior pain reduction compared to intravenous tramadol. Sleep scores were significantly better with tapentadol nasal spray. The nasal route provided enhanced comfort, convenience, safety, and efficacy, offering rapid pain relief. Conclusion: Tapentadol nasal spray presents a favorable option for post-operative pain management, offering improved pain reduction, better sleep outcomes, and enhanced patient comfort. The nasal delivery method proves efficient and patient-friendly, marking a significant advancement in achieving early and sustained pain relief.